Emma Wakeling

Emma Wakeling

Auto-generated profile, based on publicly available information

Emma Wakeling

North East Thames Regional Genetic Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GRGillian I Rice
Gillian I Rice
PKPaul Kasher
Paul Kasher
GFGabriella M A Forte
Gabriella M A Forte
NMNiamh M Mannion
Niamh M Mannion
SGSam M Greenwood
Sam M Greenwood
YCYanick J Crow
Yanick J Crow

14 June 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
GRGillian I Rice
Gillian I Rice
JBJacquelyn Bond
Jacquelyn Bond
AAAruna Asipu
Aruna Asipu
RBRebecca L Brunette
Rebecca L Brunette
IMIain Manfield
Iain Manfield
YCYanick J Crow
Yanick J Crow

2 September 2016 in Nature Reviews Endocrinology
Verified
Journal Article
Open access
PDF file
EWEmma L. Wakeling
Emma L. Wakeling
FBFrédéric Brioude
Frédéric Brioude
OLOluwakemi Lokulo-Sodipe
Oluwakemi Lokulo-Sodipe
SOSusan M. O'Connell
Susan M. O'Connell
JSJennifer Salem
Jennifer Salem
INIrène NETCHINE
Irène NETCHINE
This Consensus Statement summarizes recommendations for clinical diagnosis, investigation and management of patients with Silver–Russell syndrome (SRS), an imprinting disorder that causes prenatal and postnatal growth retardation. Considerable overlap exists between the care of individuals born small for gestational age and those with SRS. However, many specific management issues exist and evidence from controlled trials remains limited. SRS is primarily a clinical diagnosis; however, molecular testing enables confirmation of the clinical diagnosis and defines the subtype. A 'normal' result from a molecular test does not exclude the diagnosis of SRS. The management of children with SRS requires an experienced, multidisciplinary approach. Specific issues include growth failure, severe feeding difficulties, gastrointestinal problems, hypoglycaemia, body asymmetry, scoliosis, motor and speech delay and psychosocial challenges. An early emphasis on adequate nutritional status is important, with awareness that rapid postnatal weight gain might lead to subsequent increased risk of metabolic disorders. The benefits of treating patients with SRS with growth hormone include improved body composition, motor development and appetite, reduced risk of hypoglycaemia and increased height. Clinicians should be aware of possible premature adrenarche, fairly early and rapid central puberty and insulin resistance. Treatment with gonadotropin-releasing hormone analogues can delay progression of central puberty and preserve adult height potential. Long-term follow up is essential to determine the natural history and optimal management in adulthood.

1 January 2017 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
KCKeren J. Carss
Keren J. Carss
GAGavin Arno
Gavin Arno
MEMarie Erwood
Marie Erwood
JSJonathan Stephens
Jonathan Stephens
ASAlba Sanchis-Juan
Alba Sanchis-Juan
PYPing Yu
Ping Yu

22 January 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BABeverley H Anderson
Beverley H Anderson
PKPaul Kasher
Paul Kasher
JMJosephine Mayer
Josephine Mayer
MSMarcin Szynkiewicz
Marcin Szynkiewicz
EJEmma M Jenkinson
Emma M Jenkinson
YCYanick J Crow
Yanick J Crow

26 February 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JHJeroen K J Van Houdt
Jeroen K J Van Houdt
BNBeata Anna Nowakowska
Beata Anna Nowakowska
SSSérgio B Sousa
Sérgio B Sousa
BSBarbera D C van Schaik
Barbera D C van Schaik
ESEve Seuntjens
Eve Seuntjens
JVJoris Robert Vermeesch
Joris Robert Vermeesch